This study investigated the role of human insulin-like growth factor-1 (hIGF-1; encoded by the hIGF1 gene) on intervertebral disc degeneration. A total of 24 male New Zealand rabbits of an intervertebral disc degeneration (IVDD) model were randomly divided into three groups where the following were injected into the lumbar 4 -5 and 5 -6 discs: second generation adenovirus containing cytomegalovirus hIGF1 (Ad/CMV-hIGF1); 100 µg/l hIGF-1 protein; or phosphatebuffered saline. At 1, 2, 4 and 8 weeks postinjection, intervertebral disc samples were harvested. Human IGF-1 protein was detected using Western blot analysis, and aggrecan and collagen type II gene fragments were quantified using reverse transcription-polymerase chain reaction. At week 1 post-injection, hIGF-1 protein levels were similar in the Ad/CMV-hIGF1 and hIGF-1 groups. By week 2 the level had decreased substantially in the hIGF-1 group. At week 4 it was still present in the Ad/CMV-hIGF1 group and, by week 8, no protein was detected in any of the three groups. Aggrecan and collagen type II mRNA levels increased in the Ad/CMV-hIGF1 group 1 -4 weeks post-injection, but declined by week 8, while both decreased steadily over 8 weeks in the other two groups. In conclusion, hIGF1 gene expression lasted for 4 weeks and stimulated the synthesis of aggrecan and collagen type II in the Ad/CMV-hIGF1 group.
Introduction
Traditional surgical treatment for intervertebral disc disease (IVDD) has many potential problems, including spinal fusion and the degeneration of neighbouring spinal segments. Gene therapy is one of the most promising potential biological approaches. The theory behind gene therapy is that the transfer of certain genes to the pathological discs will lead to regeneration. To date, research into growth factors that promote biological activities in intervertebral disc cells has been carried out primarily in vitro; however, the conditions of cultured intervertebral disc cells differ greatly from those in the in vivo environment. 1 Thus, in vitro data on the effect of growth factors should be supported by in vivo experimental evidence.
Nucleus pulposus forms the gelatinous ZQ Huang, ZM Zheng, J Yan Human IGF1 in intervertebral degenerative discs core of intervertebral discs that maintains or restores disc height and absorbs loads applied to the spine. This is a closed system without blood vessels and is, therefore, difficult for growth factors to reach when administered outside the intervertebral disc. 2 Thus, direct injection is the preferred route of administration of growth factors for in vivo research. Lettice et al. 3 used papain to break down the intervertebral discs of adult dogs and then continuously injected epidermal and fibroblast growth factors; control discs were treated with sodium chloride. After 12 weeks the height of intervertebral discs in the treatment group had recovered greatly compared with the control group, and the proteoglycan content and cell density had also increased substantially. 3 The long-term local use of growth factor therapy has many side-effects, often requires a long treatment period that would be unacceptable to patients, and can be expensive. 2 Gene transfer provides a novel approach to maintain the effect of growth factors on intervertebral discs. Using adenovirus, Nishida et al. 4 -6 transferred the LacZ gene in vivo into the nucleus pulposus of adult rabbits and in vitro into cultured nucleus pulposus cells and found that the LacZ gene was continuously expressed for about 12 weeks. They used the same method to introduce the TGFB1 gene, which encodes transforming growth factor β1 (TGF-β1), into the nucleus pulposus tissue of adult rabbits and found that gene expression and proteoglycan concentrations increased by five-and two-fold, respectively, compared with controls. Moon et al. 7 and Nishida et al. 5 also transferred the LacZ gene into cultured human intervertebral disc cells using adenovirus and demonstrated persistent gene expression for 3 weeks after transfection. On the basis of these studies, adenovirus has been shown to be an effective vector for the transfer of therapeutic growth factor genes to unseparated cells in intervertebral disc tissue.
Compared with normal intervertebral discs, those affected with IVDD have fewer and less active cells and differ notably from normal disc cells in various biological characteristics. 8 To date, most published research has been from studies on gene transfection using adenovirus in normal intervertebral disc tissues. Thus, questions remain as to whether the cells in degenerative discs can be successfully transfected and, if they can, how gene expression changes after transfection and whether this approach can be used in the treatment of IVDD.
The present study focused on the role of gene therapy using human insulin-like growth factor-1 (hIGF-1; encoded by the hIGF1 gene) in the regeneration of intervertebral discs affected by IVDD. An in vivo rabbit model 9 was used to investigate whether, and to what degree, hIGF1 is expressed after gene transfer with the aim of determining whether gene therapy can offer a novel way to treat IVDD.
Materials and methods

PREPARATION OF HIGF1 AND VECTOR SOLUTION
A DNA sequence encoding the hIGF1 gene was synthesized as described previously 10 and was diluted with 0.01 M phosphate-buffered saline (PBS), pH 7.4. A 25 µl volume of solution containing 2.5 pg DNA per sample was used to construct the recombinant adenovirus containing cytomegalovirus hIGF1 (Ad/CMV-hIGF1) vector according to a previously described method. 11 The second-generation vector was diluted to a concentration of 2 × 10 6 plaque-forming units (PFU) per 25 µl, which constituted the dose injected into each intervertebral disc.
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INTRAVERTEBRAL DISC COLLECTION AND PROCESSING
All procedures were reviewed and approved by the Medical Ethics Committee of Sun Yetsen University for care and use of animals. A total of 24 New Zealand rabbits were used. 10 They were randomly divided into three groups: the Ad/CMV-hIGF1 group, the hIGF-I group and the PBS-only control group. After anaesthesia, the rabbits in the Ad/CMV-hIGF1 group were placed on a specifically designed operating table and laid on their right sides. Under radiographic guidance, the lumbar 4 -5 (L4 -L5) and L5 -L6 intervertebral discs were stabbed with 25gauge extraspinal dura mater transfixion pins (Molecular Medicine Centre of the Second Affiliated Hospital of Sun Yet-sen University, China). After puncture, the inner part of the transfixion pin was pulled out, and a 25-gauge lumbar anaesthesia needle was inserted ( Fig. 1) . A 25-µl aliquot of Ad/CMV-hIGF1 solution (8 × 10 10 PFU/l) was injected with a 100-µl micropipette. The same method was used to inject 25 µl of hIGF-I (100 µg/l), prepared as described previously; 10 or 0.01 M PBS, pH 7.4.
Two rabbits from each group were anaesthetized and killed with air embolism at each of 1, 2, 4 and 8 weeks post-injection. The whole lumbar segment was quickly excised, the vertebral plate and its coherence muscles were removed, and the L4 -L5 and L5 -L6 intervertebral discs were recovered. The supracartilage and infracartilage endplates were removed, and the intact annular fibrous and nucleus pulposus were reserved.
The tissue was sheared into pieces, which were then thoroughly washed with 0.01 M PBS, pH 7.4, at 0°C and centrifuged at 3000 g for 5 min at 4°C using a Hettich Universal 32R benchtop, low-temperature, high-speed centrifuge (Heraeus, Hanau, Germany). The clear supernatant liquid was removed and the tissue pieces were diluted with five times the volume of pre-cooling suspension buffer (0.1 mol/l saline, 0.01 M Tris-HCl [pH 7.6], 0.001 M ethylenediaminetetra-acetic acid [pH 8.0], 1 g/l aprotinin, 100 g/l phenylmethyl sulphonyl fluoride). An equal volume of 2 × gel-loading buffer (100 mM Tris-HCl [pH 6.8], 200 mM dithiothreitol, 4% sodium dodecyl sulphate, 0.2% bromophenol blue, 20% glycerol) for sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) was added as soon as possible. The sample was heated in boiling water, from a purified water preparation system (Labconco, Kansas City, MO, USA) for 10 min, then centrifuged at 10 000 g for 10 min at room temperature in a benchtop Eppendorf 5415c room temperature highspeed centrifuge (Eppendorf, Hamburg, Germany). The clear supernatant was transferred to another tube before testing the protein concentration of the samples.
A standard protein concentration curve was created using a protein assay kit (Bio- spinal dura mater transfixion pin and the 25-gauge lumbar anaesthesia pin that were used to inject 25 µl adenovirus solution carrying the insulin-like growth factor-1 gene into the intervertebral discs of live rabbits Human IGF1 in intervertebral degenerative discs Rad, Hercules, CA, USA) and the same kit was used to measure protein concentration in the tissue samples. Samples for detection, double-distilled water and protein staining solution were mixed evenly and incubated at room temperature for 15 min. The control sample was used as a zero value to calculate accurately the protein concentrations in the tissue samples. The optical density (OD) of the protein samples was measured at 595 nm using a UV-2201 spectrophotometer (Shimadzu, Kyoto, Japan) and compared against the standard curve.
DETECTION OF HIGF-I PROTEIN
To detect the levels of hIGF-1 protein in the samples, SDS-PAGE was carried out in 1 × Tris-amino acetic acid electrophoresis buffer (Sangon Biotech, Shanghai, China) using a total of 50 µg protein from each sample under a constant voltage of 120 V for 40 -60 min. Bromothymol blue was then injected into the separation gel and the voltage was changed to a constant 220 V and electrophoresis was continued until the dye reached the bottom of the gel. Pre-stained protein molecular weight markers (New England BioLabs, Hitchin, UK) were used as a reference.
The gel was stained with Coomassie Brilliant Blue G-250 (0.25%) on a swing bed at room temperature for 40 min. The staining solution was then removed, destaining solution was added (composition in 1 l: 100 ml glacial acetic acid, 100 ml methyl alcohol, 800 ml double-distilled water) and the gel was gently shaken until blue protein bands appeared.
Protein was transferred electrophoretically to polyvinylidene fluoride membranes by Western blotting, and the membranes were blocked using 5% non-fat milk powder solution for 60 min at room temperature and washed once with 
ANALYSIS OF GENE EXPRESSION
Aggrecan and collagen type II gene fragments were amplified by reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted from 20 mg of each tissue sample using TRIzol ® reagent (Invitrogen, Carlsblad, CA, USA) according to the manufacturer's instructions. Then 1 µg of total RNA was reversetranscribed using a Reverse Transcription System kit (Promega, Madison, WI, USA) according to the manufacturer's instructions.
The cDNA product was amplified in a 25µl reaction volume of GeneAMP ® PCR buffer (Applied Biosystems, Foster City, CA, USA), containing 1.5 mM magnesium chloride, 200 pM of dNTP, 0.5 pM each of the appropriate primers and 2.5 U of AmpliTaq Gold TM DNA polymerase (Applied Biosystems), using a GeneAmp ® PCR System 2700 (Applied Biosystems). Primers for PCR were chosen from published primers or designed from published human sequences and synthesized by Sigma-Genosys (The Woodlands, TX, USA) as follows: aggrecan sense primer, 5′-CGA GAA TCA AAT GGA GCC G-3′, antisense primer, 5′-CAC AAC ACC TTT CAC CAC GAC-3′; collagen type II sense primer, 5′-GCT CTG AAC AGC CAA ZQ Huang, ZM Zheng, J Yan Human IGF1 in intervertebral degenerative discs AGG A-3′, antisense primer, 5′-GTT TGA CAC GGA GTA GCA CC-3′; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) sense primer, 5′-ATC ACT GCC ACC CAG AAG AC-3′, antisense primer, 5′-AAA CTG TGA AGA GGG GCA GA-3′. The sizes of the amplification products were 251 bp for aggrecan, 295 bp for collagen type II and 589 bp for GAPDH. The cycling programme involved preliminary denaturation at 94°C for 0.5 min, followed by 35 cycles of denaturation at 94°C for 0.5 s, annealing at 50°C (collagen type II or GAPDH) or 60°C (aggrecan) for 0.5 s and elongation at 72°C for 0.5 s, followed by a final elongation step at 72°C for 7 min. The RT-PCR products were identified using electrophoresis on 1.5% agarose gels. The gel images were visualized under ultraviolet light and scanned for documentation.
The expression of each gene was calculated relative to GAPDH as an internal control.
STATISTICAL ANALYSES
The mean ± SD values for a total of six repeats of each experiment were calculated and statistical analyses were carried out using the SPSS ® statistical package, version 11.5 (SPSS Inc., Chicago, IL, USA) for Windows ® . One-way analysis of variance was used to compare the measurement data with homogeneity of variance test; leastsignificant difference was used when variances were equal and Tamhane's T2 multiple comparison test was used when variances were unequal. A P-value < 0.05 was considered to be statistically significant.
Results
In the Ad/CMV-hIGF1 group, Western blot analysis showed that hIGF-1 protein was present as a 7.6 kDa band up to 4 weeks after injection, and that the level of protein decreased over time and was completely absent by week 8 (Fig. 2) . At 1 week postinjection, hIGF-1 protein was observed in the Ad/CMV-hIGF1 and hIGF-1 groups at similar levels, but was absent in the PBS (control) group (Fig. 3A) . At 2 weeks post-injection, hIGF-1 protein was still present in both the Ad/CMV-hIGF1 and hIGF-1 groups, although protein levels appeared to be lower qualitatively in the hIGF-1 group than in the Ad/CMV-hIGF1 group (data not shown). At 4 weeks post-injection, hIGF-1 protein was only present in the Ad/CMV-hIGF1 group and levels had begun to decrease compared with earlier time points ( Fig. 3B) . At 8 weeks post-injection, no protein was visible in any group (data not shown).
The RT-PCR amplification product for aggrecan was between 200 and 300 bp in size and the relative level of aggrecan mRNA in the Ad/CMV-hIGF1 group increased Human IGF1 in intervertebral degenerative discs progressively from week 1 to week 4 postinjection, but had begun to decrease by 8 weeks post-injection. In the hIGF-1 group and PBS (control) group, the level of aggrecan mRNA progressively decreased from week 1 to week 8. At each time point, the aggrecan mRNA levels were significantly lower in the PBS (control) group compared with the Ad/CMV-hIGF1 group and hIGF-1 groups (P ≤ 0.001) ( Table 1) .
From week 1 to week 4 post-injection, the relative level of type II collagen mRNA in the Ad/CMV-hIGF1 group increased progressively, although it had begun to decrease by week 8. In the other two groups the level of type II collagen mRNA decreased progressively from week 1 onwards and at all time points was significantly lower in the PBS (control) group compared with the Ad/CMV-hIGF1 group and hIGF-1 groups (P < 0.001) ( Table 2 ).
Discussion
The present study demonstrated that hIGF-1 protein was present for at least 4 weeks after injection of Ad/CMV-hIGF1 vector into the intervertebral discs of rabbits with IVDD, but it was present in the discs for only 2 weeks following direct injection of hIGF-1 protein. This indicates that hIGF1 gene expression occurred in vivo; the shorter presence of hIGF-1 protein when injected directly might be due to the half-life of the protein in vivo.
In previous studies of gene therapy in normal intervertebral discs, gene expression has lasted notably longer. For example, Nishida et al. 4 -6 injected the LacZ gene directly into rabbit intervertebral discs and reported that gene expression lasted for at least 12 weeks. Paul et al. 12 injected Sox9 adenovirus directly into rabbit intervertebral discs and found that expression lasted for about 5 weeks. Similarly, Ji et al. 13 demonstrated that TGFB1 expression in intervertebral disc proteoglycan lasted for about 12 weeks. There are several possible reasons for the difference between these studies and the relatively short period of gene expression observed in the present study. First, these previous studies used normal New Zealand rabbits, whereas a rabbit model of IVDD was used in the present study; thus, the inner environments of intervertebral discs in normal and degenerative rabbit may have differed, One-way analysis of variance; b PBS (control) group statistically significantly different versus both the Ad/CMV-hIGF1 and hIGF-1 protein groups; c overall statistically significant difference across the 8 weeks.
Ad/CMV-hIGF1, adenovirus solution carrying the human insulin-like growth factor-1 gene; hIGF-1, human insulin-like growth factor-1 protein. Ad/CMV-hIGF1, adenovirus solution carrying the human insulin-like growth factor-1 gene; hIGF-1, human insulin-like growth factor-1 protein.
TABLE 1:
Relative levels of aggrecan mRNA in rabbit intervertebral disc tissue at 1, 2, 4 and 8 weeks post-injection with either Ad/CMV-hIGF1 vector, 100 µg/l hIGF-1 protein or 0.1 M phosphate-buffered saline (PBS) (control) in a rabbit model of intevertebral disc degeneration Human IGF1 in intervertebral degenerative discs leading to different outcomes. Secondly, in the present study a low-temperature, superhigh-speed centrifuge was not used to purify the transgenic vector as it was in other studies; thus, adenovirus vector used in the present study was purified differently, which may have affected the outcome. Finally, the adenovirus titres used in the present study were different from those used in the previous studies: Paul et al. 12 used 1 × 10 9 PFU and Ji et al. 13 used 6 × 10 6 PFU, compared with 2 × 10 6 PFU used in the present study. The extramolecular matrix of rabbit intervertebral discs mainly contains proteoglycan and type II collagen, and these two constituents remain stable in the inner environment of intervertebral discs of normal rabbits. 14 In 1991, Thompson et al. 15 studied the effect of several cell factors on canine intervertebral disc cells and various related reports have also been published since. 3, 16, 17 TGF-β1 is the most frequently studied growth factor, 18, 19 followed by IGF-1. 20,21 IGF-1 has multiple physiological functions, which include the promotion of cell proliferation and differentiation, participating in the body's growth and development, regulating glycometabolism, and affecting the central nervous, immune, urinary, digestive and endocrine systems. 22 -24 The capacity of growth factors to promote cell proliferation is dose-dependent, and an optimal growth-promoting concentration exists for each growth factor. 20 In intervertebral cells, IGF-1 binds to its receptor and promotes synthesis and secretion of proteoglycan, which leads to the reversal of intervertebral disc cell degeneration. 3 The optimum IGF-1 concentration for such stimulation is thought to be 100 µg/l. 3 Thus, in the present study, a concentration of 100 µg/l of hIGF-1 was selected and the protein was directly injected into the intervertebral discs. In this group, the levels of proteoglycan (agggrecan) mRNA and type II collagen mRNA decreased progressively and significantly over 8 weeks post-injection, which suggests that the possible effect of hIGF-1 on synthesis of proteoglycan and type II collagen in rabbit intervertebral disc cells, if it does exist, is probably counteracted by the progressive degeneration of intervertebral disc cells.
In 1998, Nishida et al. 6 used adenovirus to introduce an exogenous gene into experimental IVDD animal models. Several related reports on gene therapy using the same vector in an IVDD model have since been published. 16,25 -27 Injection of the Ad/CMV-hIGF1 vector in the present study resulted in an increase in levels of both hIGF-1 protein and proteoglycan (aggrecan) mRNA and type II collagen mRNA from week 1 to week 4 post-injection; although levels of protein and both mRNAs had begun to decline at 8 weeks post-injection. These results differed from those reported previously, which indicated the persistent curative effect of growth factor on degenerative intervertebral cells. 16,25 -27 The following factors might have contributed to these differences. First, the state of persistent intervertebral destabilization was obtained by cutting off the articular processes on both sides. Although reparative and destructive activity occurred alongside one another, this destabilization might have reduced the benefical effects of hIGF1 gene therapy on IVDD. Secondly, the rabbits used in the present study had obvious calcification of the end-plate cartilage. This cartilage is a nutritional pathway for intervertebral discs and its calcification could have hindered the repair process. 26 Finally, although the proteoglycan (aggrecan) and type II collagen mRNA levels increased in the gene therapy group, the extent of this increase was not substantial, suggesting that there is room for improvement in terms of achieving optimal • Received for publication 18 November 2010 • Accepted subject to revision 22 November 2010
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The present study showed that injection of the Ad/CMV-hIGF1 vector as gene therapy provided a more beneficial repair effect on rabbit IVDD cells than a single injection of hIGF-1 protein, at least in terms of stimulating the synthesis of proteoglycan (aggrecan) and type II collagen. The rabbit IVDD model is, however, clearly different from human IVDD which is a multifactorial pathological process. 28, 29 It remains unclear, therefore, whether human IVDD cells will respond to hIGF1 gene therapy and further studies, using human IVDD cells, should be done to investigate gene therapy for IVDD in clinical practice.
